Publication: Bcl-2 expression in colorectal tumours. Correlation with p53, mdm-2, Rb proteins and proliferation indices
Loading...
Date
2000
Authors
Goussia, A.C. ; Loachim, E. ; Agnantis, N.J. ; Mahera, M. ; Tsianos, E.V.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Immunostaining for bcl-2 protein was
performed in 27 colorectal adenomas and 108 colorectal
adenocarcinomas. The aim of the study was to determine
bcl-2 expression in correlation with p53, mdm-2 and Rb
expression, with proliferation indices (Ki-67-LI, PCNALI)
as well as with conventional clinicopathological
variables. A higher proportion of adenomas (30.8%)
than carcinomas (16.7%) expressed bcl-2 and
conversely, a lower proportion of adenomas (7.4%) than
carcinomas expressed p53 (57.1 %), the difference being
statistically significant (p<0.0001). No correlation of
bcl-2 expression with p53 expression (parallel or
inverse) as well as with the other parameters studied was
observed in any tumour. The bcl-2+/p53- subgroup of
cancers showed a trend for correlation with negative
lymph node status. Our data suggest, that bcl-2
expression may be involved in the early phase of
colorectal carcinogenesis regardless of p53 status, while
p53 function may be involved in a late stage of the
adenoma-carcinoma sequence. P53 is apparently not
involved in the regulation of apoptosis in the colorectal
neoplasias or perhaps bcl-2 expression, as an early event
in colorectal tumours, may occur before changes of p53
take place. Tumours with bcl-2+/p53- immunophenotype
are frequently associated with negative lymph node
status and seem to have a less aggressive behavior.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.